Toxic Epidermal Necrolysis: Case Report and Review

1 Lerch M, Mainetti C, Beretta-Piccoli BT, Harr T. Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Rev Allergy Immunol. 2018;54(1):147-76. https://doi.org/10.1007/s12016-017-8654-z PMid:29188475 Search in Google Scholar

2 Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92-6. PMid:8420497 Search in Google Scholar

3 Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults. J Invest Dermatol. 2016;136(7):1387-97. https://doi.org/10.1016/j.jid.2016.03.023 PMid:27039263 Search in Google Scholar

4 Chaby G, Maldini C, Haddad C, Lebrun-Vignes B, Hemery F, Ingen-Housz‐Oro S, et al. Incidence of and mortality from epidermal necrolysis (Stevens-Johnson syndrome/toxic epidermal necrolysis) in France during 2003-16: A four-source capture-recapture estimate. Br J Dermatol. 2020;182(3):618-24. https://doi.org/10.1111/bjd.18424 PMid:31396952 Search in Google Scholar

5 Sekula P, Dunant A, Mockenhaupt M, Naldi L, Bavinck JN, Halevy S, et al. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol. 2013;133(5):1197-204. https://doi.org/10.1038/jid.2012.510 PMid:23389396 Search in Google Scholar

6 Milosavljević MN, Pejčić AV, Milosavljević JZ. A review of published cases of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with the use of acetaminophen. Cutan Ocul Toxicol. 2021;40(3):280-92. https://doi.org/10.1080/15569527.2021.1942896 PMid:34152866 Search in Google Scholar

7 Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bavinck JN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128(1):35-44. https://doi.org/10.1038/sj.jid.5701033 PMid:17805350 Search in Google Scholar

8 Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol. 2007;56(2):181-200. https://doi.org/10.1016/j.jaad.2006.04.048 PMid:17224365 Search in Google Scholar

9 Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol. 2013;69(2):187.e1-16; quiz 203-4. https://doi.org/10.1016/j.jaad.2013.05.002 PMid:23866879 Search in Google Scholar

10 Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y, Bork K, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: Comparison with case-control analysis. Clin Pharmacol Ther. 2010;88(1):60-8. https://doi.org/10.1038/clpt.2009.252 PMid:20375998 Search in Google Scholar

11 Creamer D, Walsh SA, Dziewulski P, Exton LS, Lee HY, Dart JK, et al. U.K. guidelines for the management of Stevens- Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermat. 2016;174(6):1194-227. https://doi.org/10.1111/bjd.14530 PMid:27317286 Search in Google Scholar

12 Lee HY, Chung WH. Toxic epidermal necrolysis: The year in review. Curr Opin Allergy Clin Immunol. 2013;13(4):330-6. https://doi.org/10.1097/ACI.0b013e3283630cc2 PMid:23799330 Search in Google Scholar

13 Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14(12):1343-50. https://doi.org/10.1038/nm.1884 PMid:19029983 Search in Google Scholar

14 Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. Medical genetics: A marker for Stevens-Johnson syndrome. Nature. 2004;428(6982):486. https://doi.org/10.1038/428486a PMid:15057820 Search in Google Scholar

15 Kinoshita Y, Saeki H. A review of the pathogenesis of toxic epidermal necrolysis. J Nippon Med Sch. 2016;83(6):216-22. https://doi.org/10.1272/jnms.83.216 PMid:28133001 Search in Google Scholar

16 Devi K, George S, Criton S, Suja V, Sridevi PK. Carbamazepine-the commonest cause of toxic epidermal necrolysis and Stevens-Johnson syndrome: A study of 7 years. Indian J Dermatol Venereol Leprol. 2005;71(5):325-8. https://doi.org/10.4103/0378-6323.16782 PMid:16394456 Search in Google Scholar

17 Khalili B, Bahna SL. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol. 2006;97(3):272-80; quiz 281-3, 320. https://doi.org/10.1016/S1081-1206(10)60789-2 PMid:17042130 Search in Google Scholar

18 Torres‐Navarro I, Briz‐Redón Á, Botella‐Estrada R. Systemic therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: A SCORTEN‐based systematic review and meta- analysis. J Eur Acad Dermatol Venereol. 2021;34(1):159-71. https://doi.org/10.1111/jdv.16685 PMid:32946187 Search in Google Scholar

19 Tsai TY, Huang IH, Chao YC, Li H, Hsieh TS, Wang HH, et al. Treating toxic epidermal necrolysis with systemic immunomodulating therapies: A systematic review and network meta-analysis. J Am Acad Dermatol. 2021;84(2):390-7. https://doi.org/10.1016/j.jaad.2020.08 PMid:32898587 Search in Google Scholar